Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / PFE - Organon Vs. Viatris: Who Is The Clear Winner?

PFE - Organon Vs. Viatris: Who Is The Clear Winner?

Pfizer Inc.
  • Organon's P/E ratio was 6.5 at the end of Q1 2022, significantly lower than the pharmaceutical industry average.
  • Viatris' revenue was $4,191.7 million in the first quarter of 2022, down 5.4% from a year earlier.
  • Viatris' generic and brand drug sales have been declining year on year.
  • Organon biosimilar portfolio sales were $99 million in Q1 2022, up 22.2% from Q1 2021.
  • In 2022, Viatris sold the company's only growing product portfolio for $3.335 billion to Biocon Biologics.

For further details see:

Organon Vs. Viatris: Who Is The Clear Winner?
Stock Information
Company Name: Pfizer Inc.
Stock Symbol: PFE
Market: NYSE
Website: pfizer.com
Menu
PFE PFE Quote PFE Short PFE News PFE Articles PFE Message Board
Get PFE Alerts

News, Short Squeeze, Breakout and More Instantly...